Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

This study has been completed.
Sponsor:
Collaborator:
Cortice Biosciences, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01582152
First received: April 18, 2012
Last updated: March 30, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)